Gyre therapeutics inc GYRE.US Value Analysis
US StockHealth Care
(No presentation for GYRE)
GYRE Value Score
3
24
15
Average Growth
- AI analysis rates GYRE with a medium value score of 3.
- It is mainly due to stable revenue growth, but with concerns regarding unstable operating cash flow.
- Over the past 3 months, GYRE has maintained a consecutive value rating of 3.0, close to the rating of 2.9 over the past 3 years, indicating stable enterprise value.
- Compared to all stocks in the Health Care sector, GYRE has a medium value rating.
GYRE Value Reference Factors
The Value score is derived from various data and factor information, integrated through AI algorithms. The following factors are part of the evaluation used by AI value scores.
Update to 2025/03/22 (Weekly Update)
GYRE Financial Forecast
Unit : USD
Update to 2025/5/4 (Quarterly Update)
GYRE Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | 0.01 | - | -75% | 27.87M | - | 18.6% | 19.6% |
Update to 2025/5/7 (Quarterly Update)
GYRE Historical Value Score
You can use historical scores of 3 or above to observe potential performance and make investment decisions.
GYRE Value Strategy Backtest
The following backtest is based on specified rules since 2007. Price chart shows buy/sell time, cumulative returns, and backtesting statistics.
Entry
Exit
The Backtest Result of GYRE from 2007/01 till Now
- -47.25%
- Cumulative Return
- -3.43%
- Annual Return
- 41.70%
- Volatility
- -0.08
- Sharpe Ratio
Statistics data for entering at or above a Value score of 4 and exiting at or below a Value score of 2 from January, 2007 to May, 2025. (Total Trades: 4)
| GYRE | Sector | US Overall Market | |
|---|---|---|---|
| Wining Rate | 25% | 44% | 53% |
| Avg Return | -14.2% | 62.8% | 72% |
| Avg Profit | 1.2% | 198.9% | 166.1% |
| Avg Loss | -19.4% | -44.7% | -34.6% |
| Avg Risk-Reward Ratio | 6.1% | 444.9% | 480.1% |
Update to 2025/5/7 (Daily Update)